daclatasvir
daclatasvir: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.
daclatasvir evidence translation
What we can confirm
1 FDA record · 2 tracked trials
What it means
What to watch
Prepared research question
How could daclatasvir → BMY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) Reported 2015-07-24 · Current development: unknownSource | Approved |
| BRISTOL MYERS SQUIBB CO (BMY) Reported 2015-07-24 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen
Primary endpoint: SVR12 Rate
Frequently asked questions
Which companies have sourced relationships with daclatasvir?
daclatasvir has dated SEC/FDA relationship records for BRISTOL MYERS SQUIBB CO.
How many clinical trials involve daclatasvir?
BioSniper tracks 2 clinical trials involving daclatasvir.
What is daclatasvir's latest FDA decision?
The most recent tracked FDA decision for daclatasvir is Approval, dated July 24, 2015.